
ICLUSIG (ponatinib) patient profiles in Ph+ ALL
Watch for patients with TKI resistance/intolerance or known mutations, such as T315I
ICLUSIG may benefit specific types of patients with Ph+ ALL

Jamala | 35
Risk factors:
Hyperlipidemia (controlled)
Monitoring/testing:
Single point mutation detected (E255K)
Prior Course of Treatment:
Patient discontinued dasatinib with steroid therapy due to dasatinib intolerance

Sandraa | 61
Risk factors:
Hypertension (controlled)
Monitoring/testing:
No additional mutations detected
Prior Course of Treatment:
Patient tested positive for the T315I mutation while on dasatinib
aHypothetical patient profiles
ICLUSIG demonstrated efficacy in
Ph+ ALL
ICLUSIG has a simple dosing schedule
Ph+ ALL=Philadelphia chromosome positive acute lymphoblastic leukemia; TKI=Tyrosine kinase inhibitor.